Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta‑analysis of randomized controlled trials and cohort studies / Sohyun Kim, Yeonsook Ko, Hwa Jeong Lee, Jung‑eun Lim
Material type:
Continuing resourceISSN: 0167-6806Subject(s): breast cancer | menopausal hormone therapy | hormone replacement therapy | meta-analysis
In:
Breast Cancer Research and Treatment -- 2018, v. 170, n3, p. 667–675Summary: Purpose This meta-analysis investigated the association between the risk of breast cancer and hormone replacement therapy (HRT). Various stratifed analyses were performed according to race (Asian/Westerner), HRT type [all hormone therapies, estrogen-only therapy (ET), or combined estrogen–progestin therapy (EPT)], histological breast cancer type (ductal/lobular/mixed ductal–lobular), and estrogen receptor status (ER-positive/ER-negative).
Methods A literature search was performed using Pubmed, Embase, and KoreaMed. Twenty-fve epidemiological studies including 23 cohort studies and two randomized controlled trials were included in this meta-analysis.
Results Using a random-efects model, HRT use was found to be positively associated with the risk of breast cancer with a pooled hazard ratio (HR) of 1.33 [95% confdence interval (CI) 1.24, 1.44]. Compared with ET, EPT was more strongly associated with breast cancer risk. EPT was associated with both ductal and lobular breast cancer risks [for ductal breast cancer, HR=1.51 (95% CI 1.28, 1.78); for lobular breast cancer, HR=1.38 (95% CI 1.20, 1.60)]. According to ER status, all HRTs were associated with the risk of ER-positive breast cancer, but not with that of ER-negative breast cancer.
Conclusions Asian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were signifcantly associated with the risk of all breast cancer histological types and ER-positive breast cancer
| Item type | Current library | Collection | Call number | Status | Notes | Date due | Barcode |
|---|---|---|---|---|---|---|---|
Artículo de revista
|
Revistas y artículos | Non-fiction | PP (Browse shelf(Opens below)) | Available | Artículo de revista | 5983 |
Browsing Revistas y artículos shelves, Collection: Non-fiction Close shelf browser (Hides shelf browser)
PDF en biblioteca
Bibliografía: p.674-675
Purpose This meta-analysis investigated the association between the risk of breast cancer and hormone replacement therapy (HRT). Various stratifed analyses were performed according to race (Asian/Westerner), HRT type [all hormone therapies, estrogen-only therapy (ET), or combined estrogen–progestin therapy (EPT)], histological breast cancer type (ductal/lobular/mixed ductal–lobular), and estrogen receptor status (ER-positive/ER-negative).
Methods A literature search was performed using Pubmed, Embase, and KoreaMed. Twenty-fve epidemiological studies including 23 cohort studies and two randomized controlled trials were included in this meta-analysis.
Results Using a random-efects model, HRT use was found to be positively associated with the risk of breast cancer with a pooled hazard ratio (HR) of 1.33 [95% confdence interval (CI) 1.24, 1.44]. Compared with ET, EPT was more strongly associated with breast cancer risk. EPT was associated with both ductal and lobular breast cancer risks [for ductal breast cancer, HR=1.51 (95% CI 1.28, 1.78); for lobular breast cancer, HR=1.38 (95% CI 1.20, 1.60)]. According to ER status, all HRTs were associated with the risk of ER-positive breast cancer, but not with that of ER-negative breast cancer.
Conclusions Asian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were signifcantly associated with the risk of all breast cancer histological types and ER-positive breast cancer
There are no comments on this title.